A phenotype-oriented approach to cardiorenal-metabolic syndrome using SGLT2 inhibitors, GLP-1 receptor agonists, and MRAs is proposed to address patient heterogeneity and disease progression.
A phenotype-driven therapeutic approach using SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs is proposed to better address the heterogeneous pathophysiological drivers of cardiorenal-metabolic syndrome compared to traditional stage-based classifications.
Cardiorenal–metabolic (CKM) syndrome has emerged as a unifying condition describing the interplay between metabolic dysfunction, chronic kidney disease, and cardiovascular disease. To address this concept, the American Heart Association, in a 2023 Presidential Advisory, presented an official statement to capture the transition from metabolic risk and subtle cardiorenal dysfunction to overt cardiovascular and renal disease. Although this framework provides a structured representation of disease burden and facilitates risk stratification, emerging evidence suggests that it is primarily focused on the progressive nature, whereas high-risk patients may experience sudden cardiac or renal events. While staging systems provide important tools for risk stratification, they remain primarily descriptive and do not adequately reflect the dynamic and non-linear interactions underlying disease progression. Importantly, patients exhibit substantial heterogeneity in dominant pathophysiological drivers, related to various baseline risk factors and primitive cardio–kidney disorders, that is not fully captured by stage-based classifications. Notably, we propose a phenotype-oriented approach to CKM syndrome based on the recognition that its clinical expression reflects heterogeneous and evolving pathophysiological mechanisms rather than a uniform disease trajectory. According to this strategy, the paradigm of management shifts from an evolutive concept to a more appropriate use of disease modifying agents with cross-organ effects. Sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1a), and non-steroidal mineralocorticoid receptor antagonists (MRA) have demonstrated the ability to modulate key biological pathways across the cardiovascular, renal, and metabolic axes. Therefore, personalized management that identifies a specific strategy according to CKM phenotypes must be assessed.
Carlino et al. (Fri,) conducted a review in Cardiorenal-metabolic (CKM) syndrome. Phenotype-driven therapeutic approach (SGLT2i, GLP-1a, MRA) was evaluated. A phenotype-oriented approach to cardiorenal-metabolic syndrome using SGLT2 inhibitors, GLP-1 receptor agonists, and MRAs is proposed to address patient heterogeneity and disease progression.